Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q3 FY25
Investor Presentation
Q2 FY25
Discovery themes featuring this stockAsarfi Hospital Ltd (ASARFI) is currently trading at 213.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Asarfi Hospital Limited is an integrated healthcare services provider based in Dhanbad, Jharkhand, operating two hospitals with a combined capacity of 330 beds across a Super‑Specialty hospital and a dedicated Cancer Institute, delivering tertiary care across cardiology, neurosciences, oncology and multiple specialties to eastern India’s regional population. The company reported strong recent operating momentum with standalone Q3 FY26 revenue of ₹46.06 crore (40% YoY growth), EBITDA margins of 22% and PAT margins of 12%, reflecting a three‑year revenue CAGR of 23% and operating leverage as oncology and specialty volumes scale. Asarfi Hospital is investing strategically in high‑value clinical infrastructure: Varian TrueBeam radiotherapy, GE dual‑detector SPECT gamma camera and Philips Azurion cath lab upgrades, with targeted commissioning by March 2026 to enhance oncology diagnostics, radiation and interventional cardiology capabilities and improve referral capture across neighbouring districts. The company has strengthened institutional relationships through empanelments with state government healthcare schemes, railways and large corporates and a strategic MoU with Gleneagles Hospital, positioning Asarfi Hospital to capture under‑served tertiary demand from Jharkhand and adjacent regions while improving clinical offerings and revenue per occupied bed. Operationally, the Cancer Institute shows high ARPOB but lower occupancy (37% in Q3 FY26), indicating near‑term upside from utilization improvement, while the Super‑Specialty unit demonstrates steady ARPOB growth and diversified specialty revenue mix led by cardiology and neurosciences.
Over the past 52 weeks, Asarfi Hospital Ltd has traded between a low of ₹117.20 and a high of ₹256.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Asarfi Hospital Ltd has a market capitalization of approximately 419.22. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Asarfi Hospital Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 25.16 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 419.22 Cr, Asarfi Hospital Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Asarfi Hospital Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Asarfi Hospital Ltd is 25.16. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
2
Neutral
8
Bullish
4
Bearish
19
Neutral
9
Bullish
18
Bearish
17
Neutral
1
Bullish
14
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
255.00 | 543 Cr | 27.09 | 4.51 | 0.00 | 17.54 | 26.13 | 16.39 | ||
213.75 | 419 Cr | 25.16 | 4.29 | 0.00 | 17.06 | 16.27 | 8.62 | ||
120.10 | 250 Cr | 3120.75 | 4.15 | 0.00 | 0.13 | 1.06 | 0.10 | ||
111.20 | 250 Cr | 22.32 | 2.56 | 0.00 | 11.48 | 15.13 | 8.40 | ||
75.75 | 178 Cr | 53.16 | 1.72 | 0.00 | 2.75 | 4.05 | 2.88 | ||
9.79 | 154 Cr | 12.52 | 0.89 | 0.00 | 7.09 | 7.42 | 5.52 | ||
50.00 | 95 Cr | 22.93 | 2.76 | 0.00 | 12.05 | 13.76 | 10.98 | ||
| Median: 7 Co. | — | 111.20 | 250 Cr | 25.16 | 2.76 | 0.00 | 11.48 | 13.76 | 8.40 |
Asarfi Hospital Limited is an integrated healthcare services provider based in Dhanbad, Jharkhand, operating two hospitals with a combined capacity of 330 beds across a Super‑Specialty hospital and a dedicated Cancer Institute, delivering tertiary care across cardiology, neurosciences, oncology and multiple specialties to eastern India’s regional population.
The company reported strong recent operating momentum with standalone Q3 FY26 revenue of ₹46.06 crore (40% YoY growth), EBITDA margins of 22% and PAT margins of 12%, reflecting a three‑year revenue CAGR of 23% and operating leverage as oncology and specialty volumes scale.
Asarfi Hospital is investing strategically in high‑value clinical infrastructure: Varian TrueBeam radiotherapy, GE dual‑detector SPECT gamma camera and Philips Azurion cath lab upgrades, with targeted commissioning by March 2026 to enhance oncology diagnostics, radiation and interventional cardiology capabilities and improve referral capture across neighbouring districts.
The company has strengthened institutional relationships through empanelments with state government healthcare schemes, railways and large corporates and a strategic MoU with Gleneagles Hospital, positioning Asarfi Hospital to capture under‑served tertiary demand from Jharkhand and adjacent regions while improving clinical offerings and revenue per occupied bed.
Operationally, the Cancer Institute shows high ARPOB but lower occupancy (37% in Q3 FY26), indicating near‑term upside from utilization improvement, while the Super‑Specialty unit demonstrates steady ARPOB growth and diversified specialty revenue mix led by cardiology and neurosciences.
Healthcare Services
Hospital
419 Cr
Moderate Risk
25.2
63.3
1.0
4.3
256.95
117.20
Sales CAGR
Profit CAGR
ROE
ROCE
